Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
SYN-004
DRUG
2 trials
Sponsors
Theriva Biologics, Inc.
Conditions
Clostridium Difficile
Clostridium Infections
Healthy Volunteers With Ileostomy
Phase 1
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
Completed
NCT02473640
Theriva Biologics, Inc.
Healthy Volunteers With Ileostomy
Start: 2015-06-30
End: 2016-04-30
Updated: 2018-11-27
Phase 2
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Completed
NCT02563106
Theriva Biologics, Inc.
Clostridium Difficile, Clostridium Infections
Start: 2015-10-31
End: 2016-11-30
Updated: 2018-11-27
Related Papers
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
2019-03-15
61 citations
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
Antimicrobial Agents and Chemotherapy
2017-01-05
63 citations